Promising Schizophrenia Drug, Cobenfy, Will Likely Face Access Challenges
Insurer access challenges likely lie ahead for the novel schizophrenia drug Cobenfy, given its considerably higher price than existing atypical anti-psychotics.
FiercePharma1d
Incyte wins injunction to block launch of Sun Pharma's JAK inhibitor Leqselvi
Despite winning an alopecia areata approval for its drug Leqselvi in July, Sun Pharma will have to wait a while longer to ...
UCLA Chemists Shatter 100-Year-Old Chemistry Rule – Textbooks Need a Rewrite
UCLA chemists have overturned a century-old rule in organic chemistry that limited molecular design by proving that ...
Fostering Healthcare Innovation Through Policy, Partnerships, and Collaborative Action
The United States is home to one of the leading healthcare systems globally, primarily due to its remarkable ability to drive ...
FiercePharma4d
'It was a good lesson': FDA reconsiders CAR-T boxed warning on secondary cancers, Peter Marks says
An FDA announcement last year of an investigation into the risk of patients developing secondary cancers following the ...